Published on 22/12/2025
Designing Effective Dashboards to Track KRIs in Clinical Trials
The Role of Dashboards in RBM
As Risk-Based Monitoring (RBM) becomes the norm in clinical trials, dashboards are increasingly used to visualize Key Risk Indicators (KRIs) for timely decision-making. Rather than sifting through spreadsheets or static reports, dashboards offer real-time insights with visual cues like colors, graphs, and alerts that enable quicker responses to emerging risks.
Modern dashboards aggregate data from systems such as CTMS, EDC, eTMF, and safety databases to present a holistic view of trial health. Regulators expect sponsors and CROs to use these tools as part of quality oversight and to demonstrate proactive monitoring during inspections.
Core Design Elements of a KRI Dashboard
An effective KRI dashboard is user-centric, actionable, and visually structured. Key elements include:
- Color-coded status indicators: Green (acceptable), Yellow (warning), Red (critical)
- Trend lines: Show change in KRI values over time
- Drill-down capability: Enables site-level investigation
- KPI benchmarks: Thresholds derived from protocol-specific parameters
- Filter and export options: By site, region, CRA, or KRI type
For example, a protocol deviation rate KRI might be represented as a gauge chart with red zones indicating breaches. Check out PharmaSOP for SOPs on defining KRI thresholds and dashboard escalation policies.
Sample KRI
Below is a hypothetical layout of a KRI dashboard for a multicenter clinical trial:
| Site | SAE Reporting Lag | Protocol Deviations | Data Entry Lag | ICF Error Rate | Overall Status |
|---|---|---|---|---|---|
| Site 001 | 24h ✅ | 2.5 🚧 | 2 days ✅ | 4% ❌ | 🔴 |
| Site 002 | 18h ✅ | 1.2 ✅ | 1 day ✅ | 0.8% ✅ | 🟢 |
| Site 003 | 60h 🚧 | 3.8 ❌ | 4 days 🚧 | 2.2% 🚧 | 🟠 |
Each row in the dashboard highlights a trial site, enabling central monitors to prioritize follow-up. Traffic light visuals make it easier to digest information at a glance.
Integrating Dashboards with Source Systems
To be effective, KRI dashboards must pull data automatically from validated systems. This eliminates manual entry errors and ensures timeliness. The most common data integrations include:
- EDC (Electronic Data Capture): For data entry timestamps, queries, AE/SAE timing
- CTMS: Site visit dates, CRA reports, subject visit tracking
- eTMF: Consent forms, site documents, deviation logs
- Safety Databases: For real-time SAE reporting monitoring
Dashboards must be validated under GxP if they are used for decision-making. Tools like Tableau, Power BI, or RBM-specific platforms like Medidata Detect or CluePoints support compliance-ready visualization. See PharmaValidation for dashboard validation guidance.
Regulatory Expectations for KRI Dashboards
Regulators have acknowledged dashboard usage during audits and inspections. FDA BIMO inspections and EMA GCP inspectors may request:
- Evidence of real-time oversight using dashboards
- Defined escalation paths tied to dashboard alerts
- Audit trails showing updates, user access, and data flow
- SOPs covering visualization usage and interpretation
Documentation and training are critical. Just having a dashboard is not sufficient—it must be operational, monitored, and linked to CAPA workflows if thresholds are breached.
Best Practices in KRI Dashboard Implementation
- Limit visuals to 6–8 core KRIs to avoid clutter
- Use standard legends and colors across studies
- Establish site-specific thresholds for high-risk studies
- Refresh dashboards daily or weekly depending on trial phase
- Enable role-based access (e.g., CRA, QA, Central Monitor)
Train users not just to read dashboards, but to interpret trends and act. Integrating dashboards into weekly monitoring calls improves adoption and consistency.
Final Thoughts: Making Dashboards Work for You
KRIs provide data—but dashboards provide clarity. A well-designed dashboard is more than a visual tool; it’s an integral part of your trial oversight strategy. When used proactively, dashboards help you stay ahead of risks, improve subject safety, and ensure quality across all trial sites.